That's because there has been a string of negative developments over the past several months, including three deaths from liver failure of patients taking Sarepta's DMD drugs - which led to a pause in ...

US stocks gave up earlier gains on Tuesday as investors digested a wave of corporate earnings and economic data, while ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

US stocks pared earlier small gains on Tuesday, but kept a bid for more records in play as investors combed through a rush of ...

US stocks moved higher on Tuesday, eyeing a bid for more records as investors combed through a fresh rush of corporate ...

Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...

"This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such ...